Company Overview
Tango Therapeutics, Inc. operates as a precision oncology company dedicated to the discovery and development of therapeutic drugs tailored for defined patient populations with significant unmet medical needs. Within the broader healthcare sector, the company specifically functions in the biotechnology industry, focusing on the creation of methylthioadenosine-cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors such as TNG462. The enterprise maintains a market capitalization of $2.77 billion while generating trailing twelve-month revenue of $62.38 million and employing a workforce of 137 individuals. These valuation and revenue figures suggest that the market assigns a substantial premium to the company's pipeline assets, positioning it as a significant player in the niche field of oncology drug development despite the absence of traditional profit generation.
Financial Health
The company reported a revenue of $62.38 million for the trailing twelve-month period, while recording a net income of -$101,594,000 and an EBITDA of -$109,008,000. The substantial gap between the positive revenue of $62.38 million and the negative net income of -$101,594,000 reveals a highly aggressive cost structure where operating expenses significantly exceed sales, a common characteristic in early-stage biotechnology firms investing heavily in research and development. Free cash flow stands at -$60,859,624, indicating that the company is currently consuming cash reserves to fund its operational activities and pipeline advancement rather than generating liquidity from its core business. Gross margin is reported at -111.9%, operating margin at -178.4%, and profit margin at -162.9%, all of which are negative and indicate that the company is operating at a loss where costs are far outpacing revenue generation. In terms of liquidity and leverage, the company holds $343.14 million in cash against $33.57 million in debt, resulting in a debt-to-equity ratio of 9.70 which suggests a leveraged balance sheet relying heavily on equity financing rather than creditor capital. The current ratio is an exceptionally high 16.32, signaling robust short-term liquidity and an ability to cover liabilities many times over with available current assets. Return on Equity is -37.2% and return on assets is -19.5%, metrics that collectively reveal that management is currently utilizing shareholder and asset bases to generate losses rather than positive returns, reflecting the capital-intensive nature of the biotechnology business model.
Valuation Assessment
The company presents a trailing P/E ratio that is effectively non-existent as denoted by N/A, while the forward P/E is listed at -12.67, a metric that implies earnings are currently negative and future projections do not yet show profitability. The price-to-book ratio is 7.62, which indicates that the market values the company at a significant premium over its tangible book value, likely attributing high worth to the intellectual property and pipeline potential contained within the firm. Alternative valuation metrics such as the price-to-sales ratio of 44.42 and the EV/EBITDA of -22.58 suggest that the stock is priced based on future growth expectations and asset value rather than current earnings power. The 52-week high is $19.80 and the 52-week low is $1.03, providing a trading range where the current market price sits at a specific point within this volatility band relative to the recent highs and lows. The beta value is 1.81, which means the stock is expected to be significantly more volatile than the broader market, exhibiting amplified price movements in response to general market fluctuations.
Growth & Income
Revenue growth year-over-year is -100.0%, while earnings growth year-over-year is listed as N/A, indicating a situation where the company has not yet established a baseline of consistent positive earnings to calculate growth rates in the traditional sense. The negative revenue growth figure suggests a contraction in sales or a shift in the reporting period that impacts the top line, while the lack of earnings growth data reflects the company's status as a loss-making entity reinvesting all capital into its operations. As a non-dividend payer, the company does not distribute cash to shareholders, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning all available cash and generated income are theoretically retained to fund ongoing research, development, and capital expenditures. The overall growth and income profile is defined by high capital consumption, negative growth metrics in revenue, and a complete absence of dividend income, characteristic of a biotechnology firm in the clinical development phase prioritizing asset growth over shareholder cash distributions.